Jeffrey Lawson
Fondatore presso InnAVasc Medical, Inc.
Profilo
Jeffrey H.
Lawson is the founder of InnAVasc Medical, Inc. (founded in 2013) and holds the title of Director.
He is currently the Chief Executive Officer at VarmX BV (since 2023), Vice Chairman & Chief Surgical Officer at Humacyte Global, Inc. (since 2015), and Director at the Vascular Access Society of The Americas, Kidney Health Initiative, and Foundation For Women & Girls With Blood Disorders.
Dr. Lawson previously served as Director & Chief Surgical Officer at Humacyte, Inc. in 2021.
He obtained a doctorate degree from the University of Vermont College of Medicine in 1991.
Posizioni attive di Jeffrey Lawson
| Società | Posizione | Inizio |
|---|---|---|
Humacyte Global, Inc.
 Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Direttore/Membro del Consiglio | 01/07/2018 |
InnAVasc Medical, Inc.
 InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Fondatore | 13/05/2013 |
| Kidney Health Initiative | Direttore/Membro del Consiglio | - |
| Vascular Access Society of The Americas | Direttore/Membro del Consiglio | - |
| Foundation For Women & Girls With Blood Disorders | Direttore/Membro del Consiglio | - |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Amministratore Delegato | 12/10/2023 |
Precedenti posizioni note di Jeffrey Lawson
| Società | Posizione | Fine |
|---|---|---|
| HUMACYTE, INC. | Direttore/Membro del Consiglio | 31/12/2021 |
Formazione di Jeffrey Lawson
| University of Vermont College of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| HUMACYTE, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
| Vascular Access Society of The Americas | |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Health Technology |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
| Kidney Health Initiative | |
| Foundation For Women & Girls With Blood Disorders |
- Borsa valori
- Insiders
- Jeffrey Lawson
